Key Highlights

  • ClearOne (NASDAQ:CLRO) was down 11.68% to USD 4.99 with a Nasdaq delisting determination under appeal.
  • Cellyan Biotechnology (NASDAQ:HKPD) was up 9.29% to USD 2.00 and faces a January 11, 2027 bid price deadline.
  • Medicus Pharma (NASDAQ:MDCX) was down 11.92% to USD 1.70 after a 50-to-1 consolidation.
  • Hain Celestial Group (NASDAQ:HAIN) was up 9.62% to USD 0.1470 ahead of November 9 earnings.
  • Clean Energy Technologies (NASDAQ:CETY) was up 13.64% to USD 1.00 after a convertible note disclosure.

ClearOne (NASDAQ:CLRO) (down USD 0.6599, 11.68%): A Delisting Determination and a Pending Merger

ClearOne (NASDAQ:CLRO) was down 11.68% to USD 4.99 in pre-market trading on November 3, 2026, with an implied prior close of about USD 5.65 (calculated). No company announcement dated November 2 or November 3, 2026 was identified.

Nasdaq staff determined on October 8, 2026 to delist the shares for missing the USD 2.5 million stockholders' Equity requirement, and the company said it would request a hearing, which pauses the action. The Cortigent Merger with a Vivani Medical Subsidiary remained pending final regulatory approval as of October 30, and closing is conditioned on a USD 10.0 million to USD 15.0 million financing. Auditors have expressed Going Concern doubt, and this Penny Stock carries heavy dilution risk.

Cellyan Biotechnology (NASDAQ:HKPD) (up USD 0.1700, 9.29%): Rising After a Reverse Split

Cellyan Biotechnology (NASDAQ:HKPD) was up 9.29% to USD 2.00 in pre-market trading on November 3, 2026. The implied Monday close was about USD 1.83 (calculated). No company announcement dated October 30 to November 3, 2026 was identified, so the gain is not tied to a specific event.

A 1-for-20 reverse split took effect at market open on October 26, 2026, and Nasdaq set a January 11, 2027 deadline to regain a closing bid of at least USD 1.00. The Hong Kong company moves over-the-counter pharmaceutical products through cross-border subsidiaries and filed a shelf registration for up to USD 200 million of securities, which could lead to dilution if used.

Medicus Pharma (NASDAQ:MDCX) (down USD 0.2301, 11.92%): Volatility After a 50-to-1 Consolidation

Medicus Pharma (NASDAQ:MDCX) was down 11.92% to USD 1.70 in pre-market trading on November 3, 2026. The implied prior close is about USD 1.93 (calculated). No company press release or filing dated November 2 or November 3 was identified, and only about 1.9 million shares are outstanding.

The consolidation took effect on October 12, 2026, and Nasdaq confirmed minimum bid price compliance on October 23, though the company cautioned that continued compliance is not guaranteed. A December 2, 2026 special meeting will vote on a board-discretionary split of up to 50 post-split shares per pre-split share, which the filing says could substantially reverse the consolidation.

Hain Celestial Group (NASDAQ:HAIN) (up USD 0.0129, 9.62%): A Penny Stock Ahead of Earnings

Hain Celestial Group (NASDAQ:HAIN) was up 9.62% to USD 0.1470 in pre-market trading on November 3, 2026. No announcement tied to the move was identified. On November 2 the company said it will report fiscal 2027 first quarter results before the market opens on November 9, with a call at 8:00 AM ET.

Nasdaq granted a second compliance period through March 22, 2027, and the stock must close at or above USD 1.00 for at least 10 consecutive Business days. The company said it intends to act, including a reverse split if necessary. Total Debt was USD 558 million at June 30, 2026, and management is still pursuing a lender extension of the December maturity.

Clean Energy Technologies (NASDAQ:CETY) (up USD 0.1200, 13.64%): A Bounce Despite a Convertible Note

Clean Energy Technologies (NASDAQ:CETY) was up 13.64% to USD 1.00 in pre-market trading on November 3, 2026. No filing or press release dated October 30 to November 3 was identified, so the cause is unconfirmed.

A regulatory filing made public on October 21, 2026 disclosed an 8% convertible note of USD 500,000, convertible at 85% of the lowest traded price over the prior 10 trading days. On May 26, 2026 the company disclosed a Nasdaq notice over an unfiled Form 10-Q, and whether the filing has since been made was not confirmed. Discount-priced notes can dilute holders when converted.

Where Things Stand

All five names sit close to a Nasdaq rule, whether the USD 1.00 bid price, the equity requirement or a filing deadline. Three moved up and two moved down, and in four of the five no catalyst was identified, which leaves thin trading and reverse split mechanics as possible influences. Watch the ClearOne hearing outcome, the January 11, 2027 deadline for Cellyan Biotechnology, the December 2 meeting at Medicus Pharma, the November 9 results from Hain Celestial Group and any filing from Clean Energy Technologies addressing its notice.